Team

Our specialist team is dedicated to the pharmaceutical, biotechnology and medical technology industry.

We all have prior professional experience from pharma, biotech, medical devices, CROs, scientific institutions, or life sciences consulting. Explore each of our backgrounds below:

John Rountree

John has nearly 30 years of experience in management consulting and creating value with life sciences companies. He founded Novasecta in 2003 and has built the company by selecting and developing top quality consultants who work successfully with clients across R&D, corporate/business development and commercial disciplines. John has directed many strategic and management initiatives, achieving amongst others, strategic organisational change, major licensing deals, corporate transformation, optimised asset portfolios, and improvements in strategic partnerships.

Prior to founding Novasecta, John held senior positions in three global consulting firms. He was Head of European Operations at Integral Inc. (now Analysis Group), Director at Strategic Decisions Group (SDG) and Principal at Deloitte Haskins & Sells (now IBM/PWC). John has also raised funds for and developed start-up companies commercially, and has been an executive board member of an intracellular drug delivery spin-out from the University of Cambridge and a novel CNS screening technology start-up company.

John holds an MBA from London Business School, and an MA in Engineering, Economics and Management from Brasenose College, Oxford University.

Tony Sedgwick

Tony is a Partner with Novasecta and has almost 30 years of experience in senior executive and non-executive roles in the life sciences industry.

Tony initially worked in senior management roles at Roche for 16 years including Global Head of Clinical Operations for almost 8 years. Since 2002, he has held several executive and non-executive roles in biotech companies in Europe. As CEO, he led successful trade sales of two companies: Cambridge Biotechnology, a pain, inflammation and metabolic diseases company for £25 million and DanioLabs, a neurology and opthalmology company for £15 million. Tony also raised £17.5 million for Novacta Biosystems and £5.2 million for Silence Therapeutics. He has also been an Advisor at Blueberry Therapeutics, a drug discovery company with a nanopolymer discovery platform and at Scottish Enterprise, an economic and policy organisation supporting Scottish businesses.

Tony holds a PhD FRCPath in Pathology/Experimental Pathology from St. Bartholomew's Hospital Medical School in London.

Chris Roe

Chris has over 23 years of management consulting experience. He joined Novasecta as an Associate Partner having previously held a senior management team position in IMS Consulting Group. During his time at IMS, Chris led the Product and Portfolio Strategy Practice in EMEA and led an internal change programme to restructure the organisation of IMS’s global consulting business.

Chris also co-founded and was COO of a consulting firm that focused on the strategic use of sponsorship for clients spanning multiple market sectors including FMCG, telecoms, technology, financial services and consumer electronics. Earlier in his career, Chris was a Senior Associate at Strategic Decisions Group (SDG) where, in addition to his time at IMS Consulting Group, much of his client experience focused on the life sciences sector. Chris has led strategic projects in life cycle management, R&D, devices and market entry across multiple developed and emerging international markets.

Chris has a BSc in Management Science at what is now part of the Manchester Business School and has been tutored in Executive Leadership at IMD in Lausanne.

Brian McGee

Brian is an Engagement Manager with Novasecta and is experienced in delivering commercial strategy projects with a particular expertise in product turnaround.  

Prior to Novasecta, Brian held a variety of commercial advisory roles across GlaxoSmithKline’s pharmaceuticals businesses, most recently as the Global Insight Director for Relvar/Breo in the Respiratory business. 

Brian spent the early part of his career as a strategy consultant with the Healthcare practice of the Monitor Group (now Monitor Deloitte), where he delivered strategic engagements for corporate and government clients across Europe, the Middle East and North Africa. 

Brian holds a PhD in Cell and Organism Engineering, and an MA in Natural Sciences, both from the University of Cambridge.

Grace Ong

Grace has over 10 years of experience in the life sciences industry. At Novasecta, she has led diverse strategy and management projects including transformation of R&D organisations, portfolio management, resourcing strategy, platform and asset optimisation, and strategic marketing.

Previously, Grace was a consultant in the life sciences team at L.E.K. Consulting, supporting various due diligence and mergers and acquisitions activities for private equity, venture capital and life sciences companies before joining Dialog Devices Ltd (UK) as Corporate Development Manager. Grace spent her early career in the brand management team at Novartis UK and as a project manager at West Pharmaceutical Services (USA). She began her career as a research associate in foetal bone development at the Children’s Hospital of Philadelphia (CHOP).

Grace holds an MBA from London Business School, and a BSc in Biochemistry from Bucknell University, USA.

Mark Barber

Mark has experience in R&D and licensing. At Novasecta, Mark has assessed assets and capabilities for R&D organisation and transformation, evaluated companies and strategic fit for in/out licensing, and conducted product and pipeline reviews across multiple therapy areas.

Mark conducted his postgraduate research at the Babraham Institute at the University of Cambridge, studying regulation of cells’ internal signalling. He also worked in multiple editor roles for overseas academic researchers in publications for scientific journals.

Mark holds a PhD in Cellular Signalling from University of Cambridge, and an MSc and BSc in Biochemistry from University of Waikato, New Zealand.

Salma Ajraoui

Salma has over 6 years of experience in the pharmaceutical and medical device industry spanning academic research and life sciences consulting. 

Before joining Novasecta, Salma worked within the life sciences and healthcare consulting teams at Accenture, where she worked on R&D and Commercial consulting assignments at pharmaceutical companies and the National Health Service. Prior to consulting, Salma began her career as a Research Assistant at the University of Sheffield where she was granted the Marie Curie Fellowship collaborating with European universities and industry partners. She investigated faster acquisition techniques of Magnetic Resonance Lung Imaging for the diagnostic of respiratory diseases such as asthma, emphysema and COPD. 

Salma holds a PhD in Medical Physics from the University of Sheffield, and a B.Sc. and M.Sc. in theoretical physics from the University of Paris XI.

David Cox

David is experienced in commercial analysis and R&D. At Novasecta, David has been involved in market evaluations for new products in multiple geographies, competitor analysis, and revenue modelling. In addition, he has analysed business models across the pharmaceutical industry and conducted targeted analyses on sector challenges and R&D asset valuations.

Before joining Novasecta, David worked as an internal consultant in a leading multi-national retail company to roll out best practices across the supply chain in different countries. He also had prior roles as a synthetic organic chemist within pharmaceutical CROs, and worked at a specialist fluorination company to support business development and client expansion.

David holds a PhD in Organic Chemistry from the University of Cambridge and an MSci in Chemistry with Industrial Experience from the University of Bristol.

Christopher Pettigrew

Chris has experience in business development and licensing, as well as market and competitor analysis, capital raising, and novel R&D platforms.

Before joining Novasecta, Chris co-founded and served as CEO at Cytospan Technologies, a laboratory instrumentation company. There, he developed a biochemical platform based on cell cycle manipulation for enabling the automated measurement of cellular lifespan. This platform facilitates research and drug discovery into aging-associated diseases. Prior to that, he spent time as a researcher at the University of Toronto, where he investigated the link between rDNA recombination and the extension of yeast cell replicative lifespan.

Chris holds an Honours BSc in cellular biology and economics from the University of Toronto.

Alexandra Findelair

Alexandra is an Oxford graduate with prior experience in oncology and scientific research related to the role of calcium in VEGF signalling. She has also experience in Accounting and Public Relations with Danone and PSA Peugeot Citroën.

Before joining Novasecta Alexandra worked at the University of Oxford within the department of Pharmacology. There, she explored a novel approach to preventing tumour growth by targeting the formation of newly formed blood vessels. More specifically, she worked on developing a better understanding of calcium signalling mediated via VEGF receptor activation with both in-vitro and in-vivo experiments. In-vitro tests involved calcium imaging techniques using cultured and passaged human umbilical vein endothelial cells while mouse mesenteric arteries were utilised with wire myography (in-vivo) techniques. 

Alexandra holds a Master of Science in Pharmacology from the University of Oxford and a Bachelor of Science in Biomedical Science from the University of Warwick.

Alexander Langley

Alexander is responsible for the operational management and support of Novasecta.  He is also responsible for organising the series of Novasecta programmes and events. 

Prior to joining the firm, Alexander worked at the Medical Research Council as the principal aide to the Deputy Chief Executive. Before that, he worked as a postdoctoral research scientist at the MRC National Institute for Medical Research. 

Alexander has a PhD in Molecular Biology and an MA in Natural Sciences, both from the University of Cambridge.